Contacts for further information Media: Ambre James-Brown +45 3079 9289 [email protected] Liz Skrbkova (US) +1 609 917 0632 [email protected] Data presented simultaneously at the American Diabetes Association's 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing weight loss interventions1 When adhering to treatment, weight loss of 5%, 20%, 25%, and 30% was observed in 97.6%, 60.2%, 40.4% and 23.1% of patients respectively at 68 weeks1* The REDEFINE clinical programme is ongoing to further investigate efficacy and safety of CagriSema, including recently initiated REDEFINE 112 Bagsvrd, Denmark, 22 June - Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk's phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association's (ADA) 85th Scientific Sessions and published in NEJM
Compounds displaying absorbance of less than 30% are considered to have reduced intestinal absorption
Foundayo may cause serious side effects, including: Inflammation of the pancreas (pancreatitis)
If the molecule is broken down during digestion, your liver has to do the hard work of rebuilding it all over again
Recent 2011 instructions by the FDA promoted and encouraged Monga, et al
